Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 207

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 207
---
 including inflation, or political instability in particular economies and markets; |

| • |     | potentially adverse and/or unexpected tax consequences, including penalties due to the failure of tax planning or due to the challenge by tax authorities on the basis of transfer pricing and liabilities imposed from inconsistent enforcement; |

122

| • |     | the burden of complying with complex and changing regulatory, tax, accounting and legal requirements, many of which vary between countries; |

| • |     | different medical practices and customs in multiple countries affecting acceptance of drugs in the marketplace; |

| • |     | differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls; |

| • |     | tariffs, trade barriers, import or export licensing requirements or other restrictive actions; |

| • |     | compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; |

| • |     | workforce uncertainty in countries where labor unrest is common; |

| • |     | reduced or loss of protection of intellectual property rights in some foreign countries, and related prevalence of generic alternatives to therapeutics; and |

| • |     | becoming subject to the different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations. |

These and other risks associated with international operations may adversely affect Kineta’s ability to attain or maintain profitable operations. Future sales of Kineta’s products or its product candidates, if they are approved, will be dependent on purchasing decisions of and reimbursement from government health administration authorities, distributors and other organizations. As a result of adverse conditions affecting the global economy and credit and financial markets, including disruptions due to political instability or otherwise, these organizations may defer purchases, may be unable to satisfy their purchasing or reimbursement obligations, or may affect milestone payments or royalties for Kineta’s products or any of its product candidates that are approved for commercialization in the future. Should any of these risks materialize, this could have a material adverse effect on Kineta’s business, prospects, financial condition and results of operations. Risks Relating to Manufacturing and Commercialization The manufacture of Kineta’s product candidates is complex and Kineta may encounter difficulties in production, particularly with respect to process development or scaling-outof Kineta’s manufacturing capabilities. If Kineta encounters such difficulties, Kineta’s ability to provide supply of its product candidates for clinical trials or its products for patients, if approved, could be delayed or stopped. Kineta has not yet manufactured or processed its